Safety of Vaccines against SARS-CoV-2 among Polish Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies

被引：14

作者：

Czarnowska, Agata ^{[1
]}

Tarasiuk, Joanna ^{[1
]}

Zajkowska, Olga ^{[2
]}

Wnuk, Marcin ^{[3
]}

Marona, Monika ^{[3
]}

Nowak, Klaudia ^{[3
]}

Slowik, Agnieszka ^{[3
]}

Jamroz-Wisniewska, Anna ^{[4
]}

Rejdak, Konrad ^{[4
]}

Lech, Beata ^{[5
]}

Popiel, Malgorzata ^{[5
]}

Rosciszewska-Zukowska, Iwona ^{[6
]}

Perenc, Adam ^{[5
]}

Bartosik-Psujek, Halina ^{[6
]}

Swiderek-Matysiak, Mariola ^{[7
]}

Siger, Malgorzata ^{[7
]}

Ciach, Agnieszka ^{[7
]}

Walczak, Agata ^{[7
]}

Jurewicz, Anna ^{[7
]}

Stasiolek, Mariusz ^{[7
]}

Kania, Karolina ^{[8
]}

Dyczkowska, Klara ^{[9
]}

Kalinowska-Lyszczarz, Alicja ^{[10
]}

Galus, Weronika ^{[11
]}

Walawska-Hrycek, Anna ^{[11
]}

Krzystanek, Ewa ^{[11
]}

Chojdak-Lukasiewicz, Justyna ^{[12
]}

Ubysz, Jakub ^{[12
]}

Pokryszko-Dragan, Anna ^{[12
]}

Kapica-Topczewska, Katarzyna ^{[1
]}

Bazylewicz, Marcin ^{[1
]}

Mironczuk, Anna ^{[1
]}

Kulikowska, Joanna ^{[1
]}

Kochanowicz, Jan ^{[1
]}

Bialek, Marta ^{[13
]}

Stolarz, Malgorzata ^{[13
]}

Kubicka-Baczyk, Katarzyna ^{[14
]}

Niedziela, Natalia ^{[14
]}

Morawiec, Natalia ^{[14
]}

Adamczyk-Sowa, Monika ^{[14
]}

Podlecka-Pietowska, Aleksandra ^{[15
]}

Nojszewska, Monika ^{[15
]}

Zakrzewska-Pniewska, Beata ^{[15
]}

Jasinska, Elzbieta ^{[16
,17
]}

Zaborski, Jacek ^{[18
]}

Milewska-Jedrzejczak, Marta ^{[19
]}

Zwiernik, Jacek ^{[20
,21
]}

Zwiernik, Beata ^{[21
,22
]}

Potemkowski, Andrzej ^{[23
]}

Brola, Waldemar ^{[16
,24
]}

机构：

[1] Med Univ Bialystok, Dept Neurol, PL-15276 Bialystok, Poland

[2] Univ Warsaw, Fac Econ Sci, PL-00241 Warsaw, Poland

[3] Jagiellonian Univ Med Coll, Dept Neurol, PL-30688 Krakow, Poland

[4] Med Univ Lublin, Dept Neurol, PL-20059 Lublin, Poland

[5] Clin Hosp 2 Rzeszow, Neurol Clin, Brain Stroke Sub Unit, PL-35301 Rzeszow, Poland

[6] Rzeszow Univ, Inst Med Sci, Dept Neurol, Med Coll, PL-35310 Rzeszow, Poland

[7] Med Univ Lodz, Dept Neurol, PL-90419 Lodz, Poland

[8] Poznan Univ Med Sci, Dept Neurol, PL-61701 Poznan, Poland

[9] Poznan Univ Med Sci, Fac Med, PL-61701 Poznan, Poland

[10] Poznan Univ Med Sci, Div Neurochem & Neuropathol, PL-61701 Poznan, Poland

[11] Med Univ Silesia, Fac Med Sci Katowice, Dept Neurol, PL-40055 Katowice, Poland

[12] Wroclaw Med Univ, Dept Neurol, PL-50367 Wroclaw, Poland

[13] Reg Specialised Hosp 4 Bytom, Dept Neurol, PL-41902 Bytom, Poland

[14] Med Univ Silesia, Fac Med Sci Zabrze, Dept Neurol, PL-40055 Katowice, Poland

[15] Med Univ Warsaw, Dept Neurol, PL-02091 Warsaw, Poland

[16] Jan Kochanowski Univ, Coll Med, PL-25369 Kielce, Poland

[17] RESMEDICA, Clin Ctr, PL-25726 Kielce, Poland

[18] Miedzyleski Szpital Specjalisty, Dept Neurol & Neurorehabil, PL-04749 Warsaw, Poland

[19] Med Univ Lodz, Dept Neurol & Ischem Strokes, PL-90419 Lodz, Poland

[20] Prov Specialist Hosp, Neurol Ward, PL-10561 Olsztyn, Poland

[21] Univ Warmia & Mazury, Dept Neurol, PL-10719 Olsztyn, Poland

[22] Univ Warmia & Mazury, Clin Neurol, PL-10719 Olsztyn, Poland

[23] Univ Szczecin, Dept Clin Psychol & Psychoprophylaxis, PL-70204 Szczecin, Poland

[24] Specialist Hosp Konskie, Dept Neurol, PL-26200 Konskie, Poland

来源：

VACCINES | 2022年 / 10卷 / 05期

关键词：

disease-modifying therapies; multiple sclerosis; vaccination; adverse event; SARS-CoV-2;

D O I：

10.3390/vaccines10050763

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

(1) Background: The present study aims to report the side effects of vaccination against coronavirus disease 2019 (COVID-19) among patients with multiple sclerosis (MS) who were being treated with disease-modifying therapies (DMTs) in Poland. (2) Methods: The study included 2261 patients with MS who were being treated with DMTs, and who were vaccinated against COVID-19 in 16 Polish MS centers. The data collected were demographic information, specific MS characteristics, current DMTs, type of vaccine, side effects after vaccination, time of side-effect symptom onset and resolution, applied treatment, relapse occurrence, and incidence of COVID-19 after vaccination. The results were presented using maximum likelihood estimates of the odds ratio, t-test, Pearson's chi-squared test, Fisher's exact p, and logistic regression. The statistical analyses were performed using STATA 15 software. (3) Of the 2261 sampled patients, 1862 (82.4%) were vaccinated with nucleoside-modified messenger RNA (mRNA) vaccines. Mild symptoms after immunization, often after the first dose, were reported in 70.6% of individuals. Symptoms included arm pain (47.5% after the first dose and 38.7% after the second dose), fever/chills/flu-like symptoms (17.1% after the first dose and 20.5% after the second dose), and fatigue (10.3% after the first dose and 11.3% after the second dose). Only one individual presented with severe side effects (pro-thrombotic complications) after vaccination. None of the DMTs in the presented cohort were predisposed to the development of side effects. Nine patients (0.4%) had a SARS-CoV-2 infection confirmed despite vaccination. (4) Conclusions: Vaccination against SARS-CoV-2 is safe for people with MS who are being treated with DMTs. Most adverse events following vaccination are mild and the acute relapse incidence is low.

引用

页数：11

共 26 条

[1] COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 [J].

Achiron, Anat ;

Dolev, Mark ;

Menascu, Shay ;

Zohar, Daniela-Noa ;

Dreyer-Alster, Sapir ;

Miron, Shmuel ;

Shirbint, Emanuel ;

Magalashvili, David ;

Flechter, Shlomo ;

Givon, Uri ;

Guber, Diana ;

Stern, Yael ;

Polliack, Michael ;

Falb, Rina ;

Gurevich, Michael .

MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (06) :864-870

[2] Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America [J].

Alonso, Ricardo ;

Chertcoff, Anibal ;

Leguizamon, Felisa del, V ;

Goiry, Lorna Galleguillos ;

Eizaguirre, Maria B. ;

Rodriguez, Roberto ;

Sosa, Marta ;

Carballido, Susana ;

Cruchet, Veronica ;

De Jong-Martis, Agnes ;

Giachello, Susana ;

Henestroza, Paula ;

Ferrandina, Flavia ;

Bauer, Johana ;

Carra, Adriana ;

Silva, Berenice A. .

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (04)

[3]

[Anonymous], AKTUALNOCISZCZEPIENI

[4]

[Anonymous], RAPORT ZAKAE KORONAW

[5]

[Anonymous], CORONAVIRUS WORLDOME

[6]

[Anonymous], MS TREATMENT GUIDELI

[7]

[Anonymous], 2020, Coronavirus disease (COVID-19) Weekly Epidemiological Update

[8]

[Anonymous], COVID 19 VACCINE GUI

[9]

[Anonymous], 2017, Stata: Release 15. Statistical Software

[10] Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study [J].

Antonio Esquivel-Valerio, Jorge ;

Michele Skinner-Taylor, Cassandra ;

Andrea Moreno-Arquieta, Ilse ;

Alberto Cardenas-de la Garza, Jesus ;

Garcia-Arellano, Gisela ;

Ludivina Gonzalez-Garcia, Patricia ;

del Rocio Almaraz-Juarez, Fatima ;

Angel Galarza-Delgado, Dioncio .

RHEUMATOLOGY INTERNATIONAL, 2021, 41 (12) :2105-2108

← 1 2 3 →